Enalapril

Enalapril is a member of the ACE inhibitor class, drugs that block the renin-angiotensin-aldosterone system that governs blood pressure and fluid balance. It is itself inactive; after absorption, the liver converts it into enalaprilat, the form that inhibits the enzyme. Enalaprilat is poorly absorbed when taken by mouth, which is why the prodrug enalapril is used for oral therapy while enalaprilat is reserved for intravenous use.

Physicians prescribe enalapril for high blood pressure (hypertension), for chronic heart failure with a weakened, reduced-ejection-fraction heart, and to slow kidney damage in some people with diabetes or protein in the urine. It is frequently combined with other agents such as diuretics.

Enalapril has an unusually strong evidence base in heart failure. The CONSENSUS trial showed that adding enalapril to standard treatment reduced deaths among patients with severe heart failure ^[1], and the SOLVD trial demonstrated a survival benefit in patients with milder heart failure and reduced pumping function ^[2]. Enalapril went on to become the standard comparator against which newer heart-failure drugs were tested; in the PARADIGM-HF trial, the combination sacubitril and valsartan proved superior to enalapril in reducing death and hospitalization, a result that reshaped treatment guidelines ^[3].

As is typical of ACE inhibitors, enalapril can cause a persistent dry cough, raised blood potassium, dizziness from lowered blood pressure, and, rarely, a dangerous tissue swelling called angioedema. It can harm a developing fetus and must be avoided during pregnancy. It is available as oral tablets, with enalaprilat available as an injection ^[1][2].

Enalapril is prescription only. Common effects include a persistent dry cough, dizziness from low blood pressure, headache, and raised potassium. More serious risks are angioedema (swelling of the lips, tongue, or throat), sharp drops in blood pressure after the first dose, and worsening kidney function, especially in people with narrowing of both renal arteries. It must not be used in pregnancy because it can harm a developing baby. Pairing it with potassium supplements, potassium sparing diuretics, or the drug aliskiren raises the risk of dangerous potassium levels, and taking it alongside regular NSAIDs can blunt its effect and stress the kidneys.

Enalapril is a prodrug hydrolyzed by esterases to enalaprilat, so it has no meaningful cytochrome P450 interactions; the problems come from RAAS blockade itself.

Hyperkalemia is the recurring one. Potassium supplements, potassium-sparing diuretics, spironolactone, eplerenone, trimethoprim and heparin all add to it, and reduced renal function magnifies the effect.

NSAIDs reduce the antihypertensive response and, alongside a diuretic, can precipitate acute kidney injury through loss of prostaglandin-mediated glomerular autoregulation.

Dual RAAS blockade with an ARB or aliskiren increases hypotension, hyperkalemia and renal impairment; the aliskiren combination is contraindicated in diabetes. Sacubitril/valsartan, mTOR inhibitors and DPP-4 inhibitors each raise angioedema risk.

Injectable gold as sodium aurothiomalate has produced nitritoid reactions with enalapril: flushing, nausea, vomiting and hypotension. Lithium clearance falls and toxicity has been reported.

Checking a whole stack? Run it through interactions + stacks.

Enalapril was developed by Merck and emerged from the wave of research that followed the discovery of captopril, the first orally active angiotensin-converting enzyme inhibitor, whose own lineage traced back to peptides isolated from the venom of the Brazilian pit viper. Chemists sought a successor that would inhibit ACE without the sulfhydryl group implicated in some of captopril's side effects, and the result was enalapril, a carboxyl-containing prodrug converted in the body to its active form enalaprilat.

It received approval from the United States Food and Drug Administration in 1985 and was marketed as Vasotec. Its place in cardiology was cemented by two landmark trials: the CONSENSUS study in severe heart failure, published in 1987, and the SOLVD trial in patients with reduced ejection fraction, published in 1991, both of which demonstrated a genuine survival benefit. Enalapril remains one of the most widely prescribed ACE inhibitors and appears on the World Health Organization's List of Essential Medicines.

Enalapril is regarded as a foundational and thoroughly validated cardiovascular medicine, one of the drugs that established ACE inhibition as a cornerstone of modern heart failure and hypertension care. Its reputation rests on hard outcome data rather than surrogate measures; the CONSENSUS and SOLVD trials showed that it prolongs life, not merely that it lowers numbers on a chart. Clinicians value its predictable action, its once or twice daily oral dosing, and decades of accumulated safety experience across millions of patients. It is honest to note that, like all ACE inhibitors, it can provoke a persistent dry cough in some users, can raise potassium, and must be avoided in pregnancy. Even so, few blood pressure medications carry such a deep and reassuring evidence base, which is why enalapril continues to be a trusted first-line option worldwide.